Login to Your Account

Prodrugs Matter

Idenix Tries to Convince FDA Not All Nucs Are Created Equal

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, September 10, 2012

The demise of Bristol-Myers Squibb Co.'s hepatitis C drug BMS-986094, which BMS discontinued development of after patients in its Phase IIb study experienced heart and kidney toxicity, stretched further than just the big pharma. The FDA put a partial clinical hold on Idenix Pharmaceuticals Inc.'s related nuc IDX184 and then slapped a hold on its next-generation nuc, IDX19368, as well.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription